Macquarie Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Macquarie Group’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107K	Buy	+6,295	New	+$101K	﹤0.01%	807
2024 Q4	–	Sell	-1,473	Closed	-$10.8K	–	1668
2024 Q3	$10.8K	Sell	1,473 -20,470	-93%	-$127K	﹤0.01%	1623
2024 Q2	$125K	Hold	21,943	–	–	﹤0.01%	1581
2024 Q1	$7.48K	Buy	21,943 +20,470	+1,390%	+$139K	﹤0.01%	1601
2023 Q4	$13.2K	Hold	1,473	–	–	﹤0.01%	1615
2023 Q3	$11.4K	Hold	1,473	–	–	﹤0.01%	1607
2023 Q2	$14.3K	Buy	+1,473	New	+$15.3K	﹤0.01%	1626
2022 Q4	–	Sell	-349	Closed	-$11K	–	1778
2022 Q3	$11K	Sell	349 -1,175	-77%	-$10.2K	﹤0.01%	2338
2022 Q2	$15K	Hold	1,524	–	–	﹤0.01%	2374
2022 Q1	$19K	Sell	1,524 -3,884	-72%	-$60K	﹤0.01%	2401
2021 Q4	$124K	Buy	5,408 +4,233	+360%	+$100K	﹤0.01%	1869
2021 Q3	$26K	Buy	+1,175	New	+$18.6K	﹤0.01%	2390

Other funds holding AUPH

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Macquarie Group's AUPH Position: Q2 2026 in Review

Macquarie Group opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 6,295 shares worth $107K. The stake represents ﹤0.01% of the portfolio and ranks #807 among its holdings. This is a return to the name: Macquarie Group previously reported a position in AUPH as recently as Q3 2024.

Macquarie Group first reported a position in AUPH in Q3 2021 and has held it in 12 quarters since. The position peaked at $125K in Q2 2024. 283 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Macquarie Group held 6,295 shares of Aurinia Pharmaceuticals worth $107K as of Q2 2026.
Aurinia Pharmaceuticals was a new Macquarie Group position in Q2 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Macquarie Group's portfolio in Q2 2026, its #807 holding.
Macquarie Group first reported a position in Aurinia Pharmaceuticals in Q3 2021 and has held it in 12 quarters since.
Macquarie Group's Aurinia Pharmaceuticals position peaked at $125K in Q2 2024.
283 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.